



RESEARCH UPDATE

Dave Storms, CFA

Dave@stonegateinc.com


214-987-4121

Market Statistics in EUR

Price	€ 0.95
52 week Range	€0.93 - €1.73
Daily Vol (3-mo. average)	185,642
Market Cap (M)	€ 72.87
Enterprise Value (M)	€ 77.27
Shares Outstanding: (M)	76.5
Float (M)	36.3

Financial Summary in EUR

Cash (M)	€ 13.4
Cash/Share	€ 0.18
Est. Debt (M)	€ 17.8
Equity (M)	€ (17.2)
Equity/Share	€ (0.22)



COMPANY DESCRIPTION

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. The programs only targets diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

AB SCIENCE S.A. (ENXTPA: AB)

Overview: AB Science's latest update narrows the story around two priorities: masitinib in ALS and AB8939 in AML. The key change is not FY25 revenue, but clearer capital allocation, a more defined ALS Phase 3 setup, and a firm CTFI offer that adds potential risk-sharing around AB23005. MS and AD remain meaningful upside, but are now more partnership-led given scale and commercial requirements. Near-term focus should be ALS funding, European organizational readiness, first-patient timing, and continue AML data generation.

Masitinib in ALS: Masitinib remains AB Science's lead clinical asset. AB23005 is FDA-authorized and has initial European CTIS Stage 2 approvals in Spain, Greece, and Slovenia, supporting Phase 3 initiation planning in the US and Europe. The 408-patient, 48-week study will evaluate masitinib 4.5 mg/kg/day plus riluzole versus placebo plus riluzole, with US edaravone use permitted if initiated before baseline. The trial prospectively targets normal-progressor ALS patients without complete loss of function, improving clinical homogeneity versus the broader prior dataset.

Masitinib in ALS Pathway: AB23005 more directly reflects prior AB10015 analyses and regulatory feedback. In the targeted subgroup, AB reported a 4.04-point ALSFRS-R benefit, +20.2% relative CAFS benefit, 9-month median PFS benefit, and 12-month median OS benefit. AB also identified a potential plasma biomarker tied to microglia and mast-cell activity, adding mechanistic support to masitinib's neuroinflammation rationale. Together, trial design, patient selection, and biomarker work create a clearer framework for evaluating AB23005.

Masitinib in MS and AD: Progressive MS and AD remain part of the broader masitinib opportunity, but are now more likely to move forward through partnerships. This preserves pipeline optionality while allowing AB to focus internal resources on ALS, where the regulatory pathway and near-term development priorities are more clearly defined.

AB8939: AB8939 is becoming a visible second pillar after completing Stage 3 of the AML combination program. Stage 3 evaluated 14 days of AB8939 plus venetoclax, with Stage 4 expected to add azacitidine pending regulatory approval. Early data showed responses in all four treated patients, including one complete remission, one near-complete response, and two partial responses, in heavily pretreated patients with difficult cytogenetics. While still early, the data support continued development in AML populations where resistance and unfavorable genetics remain major unmet needs.

Financing: AB ended FY25 with €10.2M in cash and added €3.2M through an April 2026 private placement, while operating loss excluding non-recurring items declined 38% to €3.8M. Creditor deferrals help preserve cash for R&D. AB received a CTFI offer for AB23005, with excess-free coverage of €25M, extendable to €39M, intended to cover clinical failure costs and provide third-party validation of the Phase 3 design, subject to study funding and premium payment. AB paused European trial recruitment to address resource and organizational questions from European authorities, but management noted limited operational impact because ALS Phase 3 had not started and AB8939 Stage 3 was recently completed.

Valuation: We use a Discounted Cash Flow Model when valuing AB. Our model returns a valuation range of €3.20 to €5.77 with a mid-point of €4.25.

Business Overview

AB Science is a Paris-based clinical-stage biopharmaceutical company developing small molecules for diseases with high unmet need. The lead program, masitinib, is an oral tyrosine kinase inhibitor selectively targeting mast cells, macrophages, and microglia, with the Company now prioritizing Phase 3 development in ALS while preserving progressive MS and Alzheimer’s disease as partnership-led late-stage opportunities. Beyond neurodegeneration, the pipeline includes a second platform with a portfolio of synthetic agents that jointly target cancer cells, with the first asset, AB8939, in Phase 1 in AML. The Company also successfully registered a proprietary veterinary product for canine mast cell tumors, demonstrating commercial-grade CMC and pharmacovigilance capabilities.

Exhibit 1: Pipeline Overview

Proprietary Drug Portfolio

Platform	Drug / Target	Therapeutic area	Indication	Development Stage	Financing Need	Staggered Potential Milestones
Tyrosine Kinase Inhibitor	Masitinib (Veterinary)	Oncology	Canine Mast Cell Tumor	Registered in the EU (>1M€ annual sales)		
Tyrosine Kinase Inhibitor	Masitinib (Oral)	Neuro-degenerative Diseases (NDD)	Amyotrophic Lateral Sclerosis	Phase 3 Authorized	22 M€ budget	End Enrolment Read-out EAP and Launch
			Progressive Forms of Multiple Sclerosis	Phase 3 Sites initiated	To be financed through partnership	Financing
			Alzheimer’s Disease	Phase 3 Authorized		
		Blood diseases	Sickle Cell Disease ¹⁾	Phase 2 To be authorized	Fully funded by a 9M€ grant of 9M€	Biomarkers Read-out
ALDH / Microtubule	AB8939 (IV)	Hematology	Acute Myeloid Leukemia (AML)	Phase 1 Initiated	Fully Funded	Phase 1 read-Out Expansion phase Read-out
Tyrosine Kinase Inhibitor		Neuro-degenerative Diseases (NDD)		Drug Discovery		

2026 2027 2028 2029

Source: Company Reports

Execution is anchored by an experienced, stable management team led by Co-founder & CEO Alain Moussy, Scientific Chair Prof. Olivier Hermine, and CMO Dr. Christian Fassotte. This team has consistently progressed multiple late-stage programs through regulator-aligned designs and site initiations. The current strategy is more focused than prior periods, with internal resources directed toward masitinib in ALS and AB8939 in AML, while MS and AD are expected to advance through partnerships given the scale and commercial infrastructure required.

Asset Overview: Masitinib

Masitinib is an oral, selective tyrosine kinase inhibitor (TKI) designed to modulate maladaptive neuroinflammation by targeting mast cells and macrophages and microglia. The drug inhibits kinases including c-KIT, Lyn and Fyn, and CSF1R, pathways implicated in immune-cell activation and inflammatory signaling that can amplify neurodegenerative injury. AB Science’s core thesis is that dampening mast-cell and microglia and macrophage crosstalk across peripheral and central compartments can translate into disease-modifying benefit across multiple neurodegenerative settings where chronic, dysregulated inflammation is believed to contribute to progression.

Exhibit 2: Masitinib Overview

Masitinib targets mast cells

- Masitinib is designed to be a potent and selective inhibitor of c-Kit, Lyn, and Fyn kinases. These kinases play critical roles in the activation of mast cells

Masitinib targets macrophages/microglia

- Masitinib is designed to be a potent and selective inhibitor of MCSFR-1

Kinase inhibition profile of masitinib			
Cellular Target	Molecular Target	IC ₅₀ [nM]	K _d [µM]
Mast cells	KIT wild-type (WT)	20	0.008
	FYN	240	0.14
	LYN	225	0.061
Macrophages / Microglia	MCSFR-1	90	0.0076

Dubreuil 2009, PLoSONE 4(9):e7258; AB Science. Davis 2011, Nat Biotechnol; 29(11):1046

Source: Company Reports

Across programs, masitinib is positioned as an add-on therapy compatible with standard-of-care regimens rather than a replacement. In ALS, the protocol requires riluzole and permits edaravone under defined conditions. In AD, the program is designed on top of standard symptomatic therapies. This combination-ready approach is central to AB Science’s development strategy, with late-stage trials structured around clinically meaningful functional endpoints in each disease. From a safety and practicality standpoint, EMA’s most recent benefit-risk assessment considered masitinib’s safety acceptable for continued ALS development, supported by a safety database exceeding 4,300 exposed patients across studies and indications, with a substantial subset treated beyond two years. Drug-drug interactions are viewed as manageable, primarily CYP3A4, and management has indicated an oral solution is planned alongside tablets to support real-world administration.

AB Science also emphasizes a multi-layered protection strategy that combines intellectual property and regulatory exclusivities. Method-of-use protection in ALS normal and slow progressors extends to 2037 in the U.S., with orphan exclusivity and potential data exclusivity further supporting durability if approved. In MS and AD, the IP strategy remains relevant, but near-term development is now more likely to be partnership-led, allowing AB to preserve optionality while concentrating internal capital on ALS and AML.

Masitinib in ALS: Masitinib’s ALS program is anchored by prior Phase 2B/3 data (AB10015) in a pre-planned “normal progressor” population (ALSFERS-R decline <1.1 points/month), where the Company reports statistically significant functional benefit and a median progression-free survival improvement. This dataset is intended to define a prospectively enriched responder population for confirmatory testing and, importantly, to reduce heterogeneity that can obscure signal in ALS.

The confirmatory Phase 3 AB23005 trial is FDA-authorized and has received initial European CTIS Stage 2 approvals in Spain, Greece, and Slovenia, following EMA validation of the harmonized protocol. The protocol requires riluzole background therapy and permits edaravone in the U.S. if initiated prior to baseline, aligning the trial with real-world treatment patterns while maintaining a controlled framework for assessment of functional decline and survival-related outcomes.

The European Medicines Agency previously declined to grant conditional marketing authorization for masitinib in ALS based on AB10015 because, in the Agency’s view, the clinical evidence did not yet remove enough uncertainty for early approval in a heterogeneous, rapidly progressive disease. Management believes the probability of Phase 3 success is improved because AB23005 is designed to address those concerns prospectively, including tighter enrollment criteria, more statistical power, and regulator-aligned endpoints. The study will enroll approximately 408 patients, more than doubling the per-arm size of the prior responder cohort, and focuses on normal-progressor ALS patients without complete loss of function. Importantly, EMA’s benefit-risk assessment considered masitinib’s safety acceptable for continued evaluation in ALS, which supports continued development as the program moves toward confirmatory testing.

Exhibit 3: EMA Objections

EMA Assessment	Mitigation	
CGP Compliance	EMA inspection highlighted GCP deviations	<ul style="list-style-type: none"> For Phase 3, a global partner will ensure data quality and integrity.
Primary analysis population	EMA disagreed with the exclusion of fast progressors in the primary analysis after study started even if the amendment was early	<ul style="list-style-type: none"> Exclusion of Fast progressors and the definition of fast progressors have been validated by EMA’s Scientific Advisory Group Neurology Exclusion of fast progressors is prespecified in the confirmatory phase 3
Imputation of Missing Data	Missing data should be treated with a penalty in case of discontinuation.	<ul style="list-style-type: none"> Integrated in the statistical part of the confirmatory study The sample size has been inflated to detect a significant treatment effect with two conservative imputation methods, Copy Increment in Reference (CIR) and Jump to Reference (JTR)

Source: Company Reports

evaluation in ALS, which supports continued development as the program moves toward confirmatory testing.

Masitinib in Progressive MS: In progressive MS, AB Science is targeting disability progression under the hypothesis that inflammation-driven neurodegeneration remains a key driver even in more advanced disease phenotypes. The Company references prior Phase 2B/3 experience as supportive of a disability progression effect at 4.5 mg/kg/day, which underpins the rationale for confirmatory evaluation.


The Phase 3 program remains authorized in the U.S. and multiple European countries, but AB is now framing progressive MS as a partnership-led opportunity given the scale, cost, and commercial infrastructure required. The design centers on time to confirmed EDSS progression, directly addressing the endpoint that matters most

clinically in progressive disease and aligning with masitinib’s proposed mechanism of attenuating harmful immune-cell activity that may contribute to continued neurologic decline.

BTK inhibitors are a prominent competing approach in progressive MS given their ability to modulate microglia and inhibit B-cells, but AB Science frames masitinib as differentiated by adding mast-cell inhibition alongside microglia modulation. Management argues mast cells play an active role in MS biology, including orchestrating microglia activation, contributing to demyelination, increasing blood–brain barrier permeability, and being present within MS plaques where they may contribute to plaque formation and disease progression. On efficacy, BTK programs have reported a ~24% risk reduction in time to 3-month confirmed disability progression in SPMS, while AB Science cites masitinib Phase 2B data showing a positive trend across PPMS and non-relapsing SPMS and a 37% risk reduction in time to 3-month confirmed disability progression in a combined PPMS plus non-relapsing SPMS population, which the Company believes could be enhanced by the incremental mast-cell component. From a safety perspective, management highlights BTK class concerns that have included cardiac events, serious liver toxicity, and infection risk tied to B-cell targeting, whereas masitinib is described as having predominantly mild-to-moderate adverse events that are front-loaded in the first three months and generally manageable with dose adjustment, with hepatic enzyme elevations addressed through a risk management plan; the Company also emphasizes that masitinib is not an immunosuppressive drug and is therefore intended to be suitable for long-term administration if Phase 3 benefit is confirmed.

Masitinib in Alzheimer’s Disease: Masitinib’s AD program builds on prior Phase 2B/3 results (AB09004; 718 patients across two sub-studies) where the Company reports statistically significant improvement in cognition (ADAS-Cog) and daily function (ADCS-ADL) at 24 weeks for masitinib 4.5 mg/kg/day administered on top of standard of care. The thesis is that modulating neuroinflammatory components of AD biology can support cognitive and functional preservation in a population consistent with mild-to-moderate disease.

Exhibit 4: Masitinib For AD




Source: Company Reports

A confirmatory Phase 3 is authorized by the FDA and key European countries. The trial uses 24-week co-primary endpoints (ADCS-ADL and ADAS-Cog 11), with 48-week secondary measures including time to severe dementia, aiming to capture both near-term symptomatic trajectory and longer-horizon functional outcomes. As with MS, AB is now more likely to advance AD through partnerships, preserving optionality while directing internal resources toward ALS and AML.

Asset Overview: AB8939

AB8939 is an intravenous small molecule designed to target both proliferating leukemia cells and leukemia stem-cell biology in Acute Myeloid Leukemia. The candidate destabilizes microtubules to disrupt cell division while inhibiting ALDH1A1 and ALDH2, enzymes associated with cancer stem-cell survival and treatment resistance. Management positions AB8939 as a differentiated mechanism that could be additive in combination regimens and potentially active in high-risk, refractory disease.

Exhibit 5: AB8939 Problem Set



Source: Company Reports

AB8939 is in Phase 1 in relapsed and refractory AML. Monotherapy dose escalation has been completed across both a 3-day and 14-day regimen, with a maximum tolerated dose of 21.3 mg/m². Stage 3, evaluating 14 days of AB8939 plus venetoclax, was recently completed, while Stage 4, adding azacitidine, is pending regulatory approval. The goal remains to establish a recommended Phase 2 dose and generate an early efficacy and safety profile in a setting where response rates and durability remain key unmet needs.

The Company highlights composition-of-matter and method-of-use protections for AB8939, and is pursuing a strategy of linking claim language to defined AML subpopulations and combination use. If clinical activity is confirmed, management believes this approach can support commercial durability through the next decade.

Additional Assets Overview

Beyond masitinib and AB8939, AB Science’s discovery platform supports additional programs spanning mast cell-driven disease and veterinary health. However, the Company has de-prioritized mastocytosis and mast cell activation syndrome, where management views the market opportunity as lower relative to development cost. This shift allows AB to concentrate resources on masitinib in ALS and AB8939 in AML while maintaining broader optionality through partnerships and selective development. Separately, AB Science maintains a commercialized veterinary masitinib franchise registered in the EU, providing a modest recurring revenue stream and a real-world validation point for the compound class in an adjacent market.

Market Overview

ALS Market Overview: ALS is an orphan-eligible disease with a relatively small but well-defined addressable population. The Centers for Disease Control and Prevention National ALS Registry estimates ~32,893 people living with ALS in the U.S. in 2022, rising to ~36,308 by 2030 (~10.5 per 100,000). In developed markets, this translates into a limited prevalence base (relative to MS/AD), but one where payers will often reimburse high-value therapies when benefit is clear and the patient segment is easy to define. Treatment is typically “add-on” (patients may layer therapies), and uptake is driven by evidence of functional/survival benefit, tolerability, and ease of use. The competitive set includes riluzole and edaravone as broad standards, and more targeted options like tofersen for SOD1-ALS; the voluntary withdrawal of Relyvrio after a negative confirmatory study has also made the market more evidence-sensitive.

Exhibit 6: ALS Market Potential


	EUROPE	US
Global disease Prevalence	6 per 100,000	6 per 100,000
Number of ALS patients	30,000	20,000
% of patients targeted in the disease*	75%	75%
Expected market share in the label**	75%	75%
% of patients covered by insurance	90%	90%
Annual treatment price***	80K€	140K\$
Potential annual peak sales	~1bn €	~1bn \$

* Excluding fast progressor patients and excluding patients prior to complete loss of function
 ** In ALS, which is a fatal disease, patients regularly use all available treatments
 *** Based on 12 months treatment duration, as per study data

Source: Company Reports

Progressive MS Market Overview: Progressive MS sits inside a large global MS population, but the *addressable* segment for any new therapy depends heavily on label language (PPMS vs SPMS, “active” vs non-active disease, disability level, and background therapy). The most widely cited global dataset (Atlas of MS) estimates ~2.9 million people living with MS worldwide in 2023 (up from 2.8 million in 2020), supporting a growing prevalence base. Progressive phenotypes represent a minority of total MS, but they carry disproportionate unmet need because the commercial prize is slowing disability progression (not just relapse control). Pricing for established MS therapies is generally specialty-drug level with prior authorization common; in practice, physicians and payers require a clear disability-progression story before adopting a new agent broadly. The landscape is competitive-anchored by major biologics and a steady flow of late-stage programs, including BTK inhibitors-so durability tends to come from a clean endpoint win on confirmed disability progression plus a chronic-use safety/monitoring profile that fits real-world care.

Exhibit 7: MS Global Prevalence



Source: <https://atlasofms.org>

Alzheimer’s Disease Market Overview: AD is the largest prevalence opportunity of the three, but the *addressable* population is shaped by diagnosis requirements, disease stage, and the practical ability of health systems to deliver/monitor therapy. The World Health Organization estimates ~57 million people lived with dementia globally in 2021, with Alzheimer’s accounting for ~60-70% of cases (a very large underlying pool). In the U.S., the Alzheimer’s Association estimates ~7.2 million Americans age 65+ are living with Alzheimer’s in 2025-useful context for sizing near-term commercial focus in one major market. Pricing in AD can support blockbuster economics, but uptake is constrained by workflow and coverage: Medicare

has tied broad coverage for anti-amyloid antibodies to registry-style data collection, and real-world adoption depends on diagnostic confirmation, clinic capacity, and ongoing monitoring. The competitive landscape is currently led by anti-amyloid antibodies (e.g., Leqembi, Kisunla), with companies also working on formats that reduce administration burden-steps that can improve adoption over time if outcomes and safety remain acceptable.

Risks

As with any investment, there are certain risks associated with AB Science's operations as well as with the surrounding economic and regulatory environments common to the pharmaceutical industry.

- The Company has no history of net income, dividends, or cash flow and there can be no assurance that the Company will be profitable going forward. In the case that the Company cannot create enough revenue to sustain on-going business activities, the Company's most likely source of financing will be through the sale of existing securities or high-cost borrowing.
- Currently the Company has enough funds to sustain it through the foreseeable future and does not pose a going concern risk. We do however recognize that at some point the Company may need to raise more funds to sustain its operations until it begins revenue generation. Should the Company be unable to raise the necessary funds this would create a going concern risk.
- The Company is subject to regulatory risk as pharmaceutical activities are subject to laws and regulations imposed by local and state government authorities. Any future changes in the laws, regulations, agreements, or judicial rulings could impact or stop the Company from generating a profit on portions or all of its asset portfolio.
- The Company has several patents for intellectual property that the Company has developed. The Company is constantly on guard and ready to defend its intellectual property using litigation if necessary. Should judgements go against the Company this could materially weaken its edge among peers. Additionally, having to pursue litigation as mediation for any infringement could be costly for the Company, regardless of the outcome.
- Should the Company bring any or all its assets to market, there is no guarantee that a profitable market will exist for those treatments. While we have sufficient reason to believe that a market will exist for the Company's assets, this is a fast-moving industry so no guarantees can be made.

VALUATION

We use a Discounted Cash Flow Model when valuing AB. Our model returns a valuation range of €3.20 to €5.77 with a mid-point of €4.25.

Our DCF valuation incorporates a terminal growth rate of 1% and a discount rate range of 17.5% to 22.5%, with a midpoint of 20.0%. While this valuation framework is currently very conservative, it reflects the inherent execution risks associated with regulatory approval, product manufacturing, and commercial pricing, all of which are still in early stages for the Company. However, we also recognize the favorable updated pathway from AB23005.

The model also conservatively assumes peak yearly revenue of ~€500.0M based on commercialization beginning in FY29 for Masitinib to treat ALS, without significant consideration given to the remainder of Masitinib uses. As the Company advances through key milestones, we believe substantial valuation re-rating potential exists.

To highlight the significant upside, a reduction in the discount rate to ~15%, which may be warranted following successful regulatory and operational de-risking, would imply a valuation midpoint of approximately ~€8.50 per share. This highlights a generous risk/reward profile and transformative value opportunity for AB Science’s development pipeline.

Key sensitivities in our model include the timing and outcome of the FDA approval process, commercial launch execution, and market adoption rates. Positive developments across any of these variables would meaningfully impact our DCF output, presenting substantial positive re-rating potential as more certainty is established in the near term. Despite this relative uncertainty we still view the Company as undervalued.

AB Science S.A.														
Discounted Cash Flow Model														
<i>(in €M, except per share)</i>														
Estimates:	2025	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E	2036E	2037E	Terminal Value
Revenue	1.2	1.3	1.4	1.6	15.6	54.7	109.4	240.6	300.8	345.9	397.8	437.6	450.7	
Operating Income	(3.5)	(6.4)	(3.6)	(3.9)	7.8	38.3	76.6	168.4	210.6	242.1	278.5	306.3	315.5	
Less: Taxes (benefit)	-	-	-	-	0.8	7.7	19.1	42.1	52.6	60.5	69.6	76.6	78.9	
NOPAT	(3.5)	(6.4)	(3.6)	(3.9)	7.0	30.6	57.4	126.3	157.9	181.6	208.8	229.7	236.6	
Plus: Changes in WC	-	-	-	-	-	-	-	-	-	-	-	-	-	
Less: Capex	-	-	-	-	-	-	-	-	-	-	-	-	-	
Free Cash Flow	(3.5)	(6.4)	(3.6)	(3.9)	7.0	30.6	57.4	126.3	157.9	181.6	208.8	229.7	236.6	1,257.9
Discount period - months	6	18	30	42	54	66	78	90	102	114	126	138	150	
Discount period - years	0.5	1.5	2.5	3.5	4.5	5.5	6.5	7.5	8.5	9.5	10.5	11.5	12.5	
Discount factor	0.91	0.76	0.63	0.53	0.44	0.37	0.31	0.25	0.21	0.18	0.15	0.12	0.10	
PV of FCF	(3.2)	(4.9)	(2.3)	(2.1)	3.1	11.2	17.6	32.2	33.5	32.1	30.8	28.2	24.2	128.8
Valuation:														
Shares outstanding	76.5													
PV of FCF	200.6													
PV of Terminal Value	128.8													
Enterprise Value	329.3													
less: Net Debt	4.4													
Estimated Total Value:	324.9													
Est Equity Value/share:	€ 4.25													
Price	€ 0.95													
Sensitivity Analysis:														
		Terminal Growth Rates												
		0.0%	0.5%	1.0%	1.5%	2.0%								
Discount rate	15.00%	€ 7.50	€ 7.65	€ 7.80	€ 7.96	€ 8.14								
	17.50%	€ 5.51	€ 5.59	€ 5.68	€ 5.77	€ 5.87								
	20.00%	€ 4.15	€ 4.19	€ 4.25	€ 4.30	€ 4.36								
	22.50%	€ 3.17	€ 3.20	€ 3.24	€ 3.27	€ 3.30								
	25.00%	€ 2.46	€ 2.48	€ 2.50	€ 2.53	€ 2.55								

Source: Company Reports; Stonegate Capital Markets

INCOME STATEMENT

AB Science S.A.

Consolidated Statements of Income (in €M, except per share amounts)

Fiscal Year End: December

	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	Q2 Jun-23	Q4 Dec-23	FY 2023	Q2 Jun-24	Q4 Dec-24	FY 2024	Q2 Jun-25	Q4 E Dec-25	FY 2025E	Q2 E Jun-26	Q4 E Dec-26	FY 2026E	Q2 E Jun-27	Q4 E Dec-27	FY 2027E
Revenue	€ 1.7	€ 1.7	€ 1.6	€ 1.6	€ 1.6	€ 1.0	€ 0.4	€ 0.5	€ 1.0	€ 0.6	€ 0.5	€ 1.1	€ 0.5	€ 0.5	€ 1.1	€ 0.6	€ 0.6	€ 1.2	€ 0.6	€ 0.7	€ 1.3
Total Revenues	1.7	1.7	1.6	1.6	1.6	1.0	0.4	0.5	1.0	0.6	0.5	1.1	0.5	0.5	1.1	0.6	0.6	1.2	0.6	0.7	1.3
Operating Expenses:																					
Cost of Goods Sold	0.1	0.2	0.2	0.1	0.1	0.0	0.2	0.2	0.4	0.1	(0.3)	(0.2)	0.4	0.3	0.7	0.4	0.4	0.7	0.4	0.4	0.7
Gross Profit	1.6	1.5	1.4	1.5	1.5	0.9	0.2	0.4	0.6	0.5	0.8	1.2	0.2	0.2	0.4	0.2	0.2	0.5	0.3	0.3	0.6
SG&A	3.3	3.5	3.3	3.4	4.1	3.5	1.9	1.7	3.5	1.5	1.9	3.4	1.0	1.5	2.5	1.5	1.5	3.0	1.5	1.5	3.0
R&D	26.7	26.9	15.6	12.8	11.2	13.3	7.2	3.3	10.5	2.6	1.4	3.9	1.8	2.0	3.8	2.0	2.0	4.0	2.0	2.0	4.0
Total Operating Expenses	30.0	30.4	18.9	16.3	15.3	16.9	9.1	4.9	14.0	4.0	3.3	7.3	2.9	3.5	6.4	3.5	3.5	7.0	3.5	3.5	7.0
Operating Income	(28.4)	(28.9)	(17.5)	(14.7)	(13.8)	(15.9)	(8.9)	(4.6)	(13.4)	(3.6)	(2.5)	(6.1)	(2.7)	(3.3)	(6.0)	(3.3)	(3.3)	(6.5)	(3.2)	(3.2)	(6.4)
Net Interest	0.0	0.0	(0.0)	(0.1)	(0.0)	(0.8)	(0.8)	(0.5)	(1.3)	(0.5)	(0.4)	(0.9)	(0.5)	(0.5)	(1.0)	(0.5)	(0.5)	(1.0)	(0.5)	(0.5)	(1.0)
FX Gains/Losses	(0.0)	0.0	(0.1)	0.2	(0.0)	0.1	0.1	0.3	0.4	(0.0)	(0.0)	(0.1)	0.1	-	0.1	-	-	-	-	-	-
Other	1.3	2.8	(4.2)	(0.4)	(0.6)	3.0	(0.9)	3.2	2.3	(0.3)	(0.4)	(0.8)	(2.1)	(0.5)	(2.6)	(0.5)	(0.5)	(1.0)	(0.5)	(0.5)	(1.0)
Profit Before Taxes	(27.1)	(26.1)	(21.7)	(15.0)	(14.4)	(13.6)	(10.4)	(1.6)	(12.0)	(4.5)	(3.4)	(7.8)	(5.2)	(4.3)	(9.4)	(4.3)	(4.3)	(8.5)	(4.2)	(4.2)	(8.4)
Provision for Income Tax	0.0	0.0	0.0	0.0	0.0	0.0	(0.0)	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Stockholders	(27.122)	(26.061)	(21.747)	(15.045)	(14.463)	(13.615)	(10.411)	(1.574)	(11.985)	(4.469)	(3.362)	(7.831)	(5.177)	(4.262)	(9.439)	(4.284)	(4.259)	(8.542)	(4.227)	(4.200)	(8.426)
EPS	€ (0.76)	€ (0.68)	€ (0.55)	€ (0.34)	€ (0.30)	€ (0.29)	€ (0.22)	€ (0.03)	€ (0.24)	€ (0.09)	€ (0.06)	€ (0.15)	€ (0.09)	€ (0.07)	€ (0.16)	€ (0.07)	€ (0.07)	€ (0.15)	€ (0.07)	€ (0.07)	€ (0.14)
WTD Shares Out	35.9	38.1	39.6	43.9	47.5	47.1	47.3	51.8	49.5	49.7	54.9	52.3	58.3	58.3	58.3	58.3	58.3	58.3	58.3	58.3	58.3

Source: Company Reports, CapIQ, and Stonegate Capital Partners estimates

IMPORTANT DISCLOSURES AND DISCLAIMER

- (a) The research analyst and/or a member of the analyst's household do not have a financial interest in the debt or equity securities of the subject company.
- (b) The research analyst responsible for the preparation of this report has not received compensation that is based upon Stonegate's investment banking revenues.
- (c) Stonegate or any affiliate have not managed or co-managed a public offering of securities for the subject company in the last twelve months, received investment banking compensation from the subject company in the last 12 months, nor expects or receive or intends or seek compensation for investment banking services from the subject company in the next three months.
- (d) Stonegate Capital Partners has a contractual agreement with the subject company to provide research services, investor relations support, and investor outreach. SCP receives a monthly retainer for these non-investment banking services.
- (e) Stonegate or its affiliates do not beneficially own 1% or more of any class of common equity securities of the subject company.
- (f) Stonegate does not make a market in the subject company.
- (g) The research analyst has not received any compensation from the subject company in the previous 12 months.
- (h) Stonegate, the research analyst, or associated person of Stonegate with the ability to influence the content of the research report knows or has reason to know of any material conflicts of interest at the time of publication or distribution of the research report.
- (i) No employee of Stonegate has a position as an officer or director of the subject company.

Ratings - Stonegate does not provide ratings for the covered companies.

Distribution of Ratings - Stonegate does not provide ratings for covered companies.

Price Chart - Stonegate does not have, nor has previously had, a rating for its covered companies.

Price Targets - Stonegate does not provide price targets for its covered companies. However, Stonegate does provide valuation analysis.

Regulation Analyst Certification:

I, Dave Storms, CFA, hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report.

For Additional Information Contact:

Stonegate Capital Partners, Inc.
Dave Storms, CFA
Dave@stonegateinc.com
214-987-4121

Please note that this report was originally prepared and issued by Stonegate for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of Stonegate should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. The information contained herein is based on sources which we believe to be reliable but is not necessarily complete and its accuracy cannot be guaranteed. Because the objectives of individual clients may vary, this report is not to be construed as an offer or the solicitation of an offer to sell or buy the securities herein mentioned. This report is the independent work of Stonegate Capital Partners and is not to be construed as having been issued by, or in any way endorsed or guaranteed by, any issuing companies of the securities mentioned herein. The firm and/or its employees and/or its individual shareholders and/or members of their families and/or its managed funds may have positions or warrants in the securities mentioned and, before or after your receipt of this report, may make or recommend purchases and/or sales for their own accounts or for the accounts of other customers of the firm from time to time in the open market or otherwise. While we endeavor to update the information contained herein on a reasonable basis, there may be regulatory, compliance, or other reasons that prevent us from doing so. The opinions or information expressed are believed to be accurate as of the date of this report; no subsequent publication or distribution of this report shall mean or imply that any such opinions or information remains current at any time after the date of this report. All opinions are subject to change without notice, and we do not undertake to advise you of any such changes. Reproduction or redistribution of this report without the expressed written consent of Stonegate Capital Partners is prohibited. Additional information on any securities mentioned is available on request.